1,415 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Bought by Jackson Square Capital LLC

Jackson Square Capital LLC bought a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the third quarter, according to its most recent filing with the SEC. The firm bought 1,415 shares of the company’s stock, valued at approximately $518,000.

Several other hedge funds have also bought and sold shares of ONC. Renaissance Technologies LLC acquired a new position in BeOne Medicines during the first quarter worth $19,438,000. Sanders Morris Harris LLC bought a new position in shares of BeOne Medicines in the third quarter valued at $1,134,000. Rokos Capital Management LLP acquired a new position in shares of BeOne Medicines during the first quarter valued at about $4,256,000. Generali Investments Management Co LLC acquired a new position in shares of BeOne Medicines during the second quarter valued at about $2,280,000. Finally, SEB Asset Management AB bought a new stake in shares of BeOne Medicines during the first quarter worth about $16,653,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Stock Up 0.6%

ONC traded up $2.29 during mid-day trading on Monday, reaching $371.35. 148,331 shares of the stock were exchanged, compared to its average volume of 308,491. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The stock has a market capitalization of $40.77 billion, a PE ratio of 65.33 and a beta of 0.61. The company has a 50 day moving average price of $360.42 and a two-hundred day moving average price of $321.92. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.40 by $0.65. The company had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ONC shares. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Morgan Stanley reissued an “overweight” rating and set a $425.00 price objective on shares of BeOne Medicines in a report on Friday. Wolfe Research reissued an “outperform” rating and set a $370.00 price objective on shares of BeOne Medicines in a report on Monday, August 10th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Finally, Truist Financial raised their target price on BeOne Medicines from $418.00 to $420.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $407.07.

Insiders Place Their Bets

In other BeOne Medicines news, COO Xiaobin Wu sold 280 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 54,892 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total transaction of $19,659,569.80. Following the completion of the sale, the chief executive officer owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. This trade represents a 18.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 408,943 shares of company stock worth $143,789,644 in the last ninety days. 6.19% of the stock is owned by corporate insiders.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.